Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Meta Expands AI Training With Employee Activity Tracking Tools 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
NEW HAVEN, Conn., March 03, 2016 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
- Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:00 a.m. ET at the Boston Marriott Copley Place in Boston, MA; and
- Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 8:30 a.m. ET at The Loews Miami Beach Hotel in Miami, FL.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company seeks to employ a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected] Media: Liz Power Achillion Pharmaceuticals, Inc. Tel: (203) 752-5509 [email protected]
